RPG LIFE SCIENCES LTD.

RPG Life Sciences Ltd has received a disclosure under SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011, from Clarus Capital I and its associated entities. The acquirer, along with persons acting in concert, has increased its shareholding in RPG Life Sciences. The total holding before the transaction was 6.81%, and after the acquisition, it stands at 7.04%. This represents a net increase of 0.23% in shareholding. The acquisition was made through open market purchases, with the latest transaction on September 25, 2026, involving the purchase of 37,463 shares.

RPG Life Sciences Ltd's subsidiary, RPG Active Pharma Limited (RPGAP), has approved a Scheme of Amalgamation with its wholly-owned subsidiary, Actis Generics Private Limited. The amalgamation, subject to NCLT and shareholder approvals, aims to streamline corporate structure, consolidate assets and liabilities, and improve operational efficiencies. Actis Generics reported a net worth of ₹34.60 Crore and revenue of ₹45.96 Crore in FY26, while RPGAP had a net worth of ₹34.75 Crore as of March 31, 2026. The merger is expected to create cost savings, enhance the balance sheet, and improve business synergy.

RPG Life Sciences Ltd has announced the closure of its trading window for designated persons and their immediate relatives. This closure will be effective from October 1, 2026, and will remain in effect until 48 hours after the declaration of the company's unaudited financial results for the quarter and half-year ending September 30, 2026. The specific date for the board meeting to consider these results will be communicated later. This measure is in compliance with SEBI regulations and the company's internal code of conduct.

RPG Life Sciences Ltd has issued a clarification regarding a recent increase in trading volume. The company stated that all material information required under SEBI regulations has been disclosed. They confirmed there are no unpublished events or information that could impact the share price or volume. RPG Life Sciences attributes the trading volume increase purely to market conditions and is unaware of any specific reasons for the movement.

RPG Life Sciences Ltd announced the completion of its Share Purchase Agreement (SPA) with Actis Generics Private Limited. The transaction, initially announced on July 29, 2026, has been finalized as of September 24, 2026. Consequently, Actis Generics Private Limited has become a subsidiary of RPG Life Sciences Ltd and a wholly owned subsidiary of RPG Active Pharma Limited (RPGAP). This acquisition marks a significant step in RPG Life Sciences' strategic growth and expansion plans.

RPG Life Sciences Ltd announced that its wholly owned subsidiary, RPG Active Pharma Limited (RPGAP), has successfully allotted securities to India Life Sciences Fund IV Domestic (ILSF) and Vistaject Fund (VJF). This allotment, valued at INR 243.33 crores, represents 40% of RPGAP's equity share capital. The transaction is in line with the Investment and Shareholders' Agreement executed on July 29, 2026. Following this investment, RPGAP continues to remain a subsidiary of RPG Life Sciences Ltd. The company has informed the stock exchanges about the completion of this significant funding round.

RPG Life Sciences Ltd has issued an update regarding an Analyst/Institutional call held on September 3, 2026. The company has made the relevant details from this call available on its official website. This communication follows previous letters dated September 2 and September 3, 2026, and serves to inform stakeholders about the availability of information discussed during the call.

RPG Life Sciences Limited announced that its wholly owned subsidiary, RPG Active Pharma Limited (RPGAP), has entered into a Business Transfer Agreement to acquire the Active Pharmaceutical Ingredients (API) and Intermediates business of Raghava Life Sciences Private Limited for a consideration up to ₹135 crore. This acquisition, subject to customary closing conditions and regulatory approvals, is a strategic move to bolster RPGAP's integrated API play. The acquired business includes a state-of-the-art EU-GMP approved plant with approximately 300 KL installed capacity, a portfolio of 22 commercialized APIs and 7 under development across key therapeutic segments. This is RPGAP's second strategic acquisition, following Actis Generics, aimed at creating a scaled API company with expanded manufacturing footprint, product portfolio, customer base, and export opportunities.

RPG Life Sciences Ltd announced that its wholly-owned subsidiary, RPG Active Pharma Limited, has executed a Business Transfer Agreement with Raghava Life Sciences Private Limited to acquire the latter's Active Pharmaceutical Ingredients (APIs) and intermediates business. The acquisition, valued at up to ₹135 crores, will be conducted as a slump sale on a going concern basis. The acquired business includes facilities, a portfolio of 29 API molecules (22 commercialized, 7 in development), and generated approximately ₹19 crores in FY26 unaudited revenue. This move aligns with RPG Life Sciences' strategy to expand its API business. The transaction is expected to be completed within 30 days, subject to regulatory approvals.

RPG Life Sciences Ltd announced that its wholly-owned subsidiary, RPG Active Pharma Limited, will acquire the Active Pharmaceutical Ingredients (APIs) and intermediates business of Raghava Life Sciences Private Limited via a slump sale. The transaction, valued at up to ₹135 crores, includes manufacturing and R&D facilities, and a portfolio of 29 API molecules. This acquisition aligns with the company's strategy to expand its API business. The deal is expected to be completed within 30 days, subject to regulatory approvals.